The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism

Bibliography

• Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-2
   PubMed Web of Science ®Google Scholar
• Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011;14:65-74
   PubMedGoogle Scholar
• Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S
   PubMed Web of Science ®Google Scholar
• Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994;344:1739-42
   PubMed Web of Science ®Google Scholar
• Monroe D, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9
   PubMed Web of Science ®Google Scholar
• McMichael M. New models of hemostasis. Top Companion Anim Med 2012;27:40-5
   PubMed Web of Science ®Google Scholar
• Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006;32(Suppl 1):32-8
   PubMed Web of Science ®Google Scholar
• Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-47
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22
   PubMed Web of Science ®Google Scholar
• Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-55
   PubMed Web of Science ®Google Scholar
• Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010;103:62-70
   PubMed Web of Science ®Google Scholar
• Ben-Hadj-Khalifa S, Hezard N, Almawi WY, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis 2011;22:369-73
   PubMed Web of Science ®Google Scholar
• Hara T, Yokoyama A, Ishihara H, et al. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994;71:314-19
   PubMed Web of Science ®Google Scholar
• Morishima Y, Tanabe K, Terada Y, et al. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997;78:1366-71
   PubMed Web of Science ®Google Scholar
• Fujii Y, Takahashi M, Morita H, et al. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant. Drug Metab Pharmacokinet 2007;22:26-32
   PubMed Web of Science ®Google Scholar
• Nagata T, Yoshino T, Haginoya N, et al. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl) cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxam ide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa. Bioorg Med Chem 2009;17:1193-206
   PubMed Web of Science ®Google Scholar
• Escolar G, Diaz-Ricart M. Edoxaban Tosilate a Direct Factor Xa Inhibitor. Drugs Future 2009;34:861-72
   Web of Science ®Google Scholar
• Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008;6:1542-9
   PubMed Web of Science ®Google Scholar
• Fukuda T, Kamisato C, Honda Y, et al. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin. Thromb Res 2013;131:540-6
   PubMed Web of Science ®Google Scholar
• Samama MM, Mendell J, Guinet C, et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012;129:e77-82
   PubMed Web of Science ®Google Scholar
• Morishima Y, Furugohri T, Honda Y, et al. Antithrombotic properties of DU-176b, a novel orally active factor Xa inhibitor: inhibition of both arterial and venous thrombosis, and combination effects with other antithrombotic agents. J Thromb Haemost 2005;3:P511
   Google Scholar
• Morishima Y, Furugohri T, Isobe K, et al. DU-176b, an oral and direct factor Xa inhibitor: in vitro pharmacological profile, pharmacodynamics, and antithrombotic effects. J Pharmacol Sci 2006;100:168P
   Web of Science ®Google Scholar
• Morishima Y, Furugohri T, Isobe K, et al. In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b. Blood 2004;104:1862
   Web of Science ®Google Scholar
• Fukuda T, Matsumoto C, Honda Y, et al. Antithrombotic effects of a direct factor Xa inhibitor, DU-176b, and an antithrombin dependent factor Xa inhibitor, fondaparinux, on an ex vivo capillary perfusion chamber thrombosis model in rats. J Thromb Haemost 2005;3(Supp1):P0612
   PubMedGoogle Scholar
• Shibano T, Tsuji N, Fukuda T, Morishima Y. Comparison of antithrombotic properties of a direct Fxa inhibitor, DU-176b, with an antithrombin dependent Fxa inhibitor, fondaparinux, in a capillary perfusion chamber thrombosis model. J Thromb Haemost 2007;5:PT 640
   Google Scholar
• Shirasaki Y, Morishima Y, Shibano T. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats. Thromb Res 2013;132:e234-9
   PubMedGoogle Scholar
• Furugohri T, Isobe K, Honda Y, et al. Pharmacological characterization, antithrombotic and bleeding effects of DU-176b, a novel, potent and orally active direct inhibitor of factor Xa: a wider safety margin of antithrombotic and bleeding effects compared to heparin, LMWH and warfarin. J Thromb Haemost 2005;3:P1110
   Google Scholar
• Morishima Y, Honda Y, Kamisato-Matsumoto C, Shibano T. Treatment of venous thrombosis with the oral direct factor Xa inhibitor Du-176b in conscious rats. Thromb Haemost 2009;7(Suppl 2): P406
   Google Scholar
• Morishima Y, Honda Y, Kamisato C, Shibano T. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats. Thromb Res 2013;132:234-9
   PubMed Web of Science ®Google Scholar
• Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53
   PubMed Web of Science ®Google Scholar
• Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev 2013;2:358-66
   PubMed Web of Science ®Google Scholar
• Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012;40:2250-5
   PubMed Web of Science ®Google Scholar
• Masumoto H, Yoshigae Y, Watanabe K, et al. In vitro metabolism of edoxaban and the enzymes involved in th eoxidative metabolism of edoxaban. Am Assoc Pharm Sci J 2010;12(Suppl 2): Abstract W4308
   Google Scholar
• Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2011;51:687-94
   PubMed Web of Science ®Google Scholar
• Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013;13:331-42
   PubMed Web of Science ®Google Scholar
• Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012;107:925-36
   PubMed Web of Science ®Google Scholar
• Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol 2012;60:335-41
   PubMed Web of Science ®Google Scholar
• Mendell J, Lee F, Chen S, et al. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor xa inhibitor. J Cardiovasc Pharmacol 2013;62:212-21
   PubMed Web of Science ®Google Scholar
• Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007;98:883-8
   PubMed Web of Science ®Google Scholar
• Fuji T, Wang CJ, Fujita S, et al. Edoxaban in patients undergoing total hip arthroplasty: a phase IIb dose-finding study. ASH Annual Meeting Abstracts 2009;114:2098
   Google Scholar
• Samama MM, Kunitada S, Oursin A, et al. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. Thromb Res 2010;126:e286-93
   PubMed Web of Science ®Google Scholar
• Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010;8:2458-68
   PubMed Web of Science ®Google Scholar
• Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010;104:642-9
   PubMed Web of Science ®Google Scholar
• Fuji T, Wang CJ, Fujita S, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: The STARS E-3 trial. Pathophysiol Haemost Thromb 2010;37
   Google Scholar
• Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. trial. Blood 2010;116:1360
   PubMed Web of Science ®Google Scholar
• Fuji T, Fujita S, Tachibana S, Kawai Y. Edoxaban versus enoxaparin for the prevention of venous thromboembolism: pooled analysis of venous thromboembolism and bleeding from STARS E-3 and STARS J-V. Blood 2011;118:97
   Web of Science ®Google Scholar
• Fujita S, Fuji T, Tachibana S, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Pathophysiol Haemost Thromb 2010;37:A94
   Google Scholar
• The HOKUSAI-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
   PubMed Web of Science ®Google Scholar
• Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol 2013;75:966-78
   PubMed Web of Science ®Google Scholar
• Mendell J, Noveck I, Rubets I, et al. The factor Xa inhibitor DU-176b is safe in healthy subjects 24 h post warfarin treatment: a randomized, double-blind study. Thromb Haemost 2009;7:P179
   Google Scholar
• Zahir H, Matsushima N, Halim AB, et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost 2012;108:166-75
   PubMed Web of Science ®Google Scholar
• Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104:1263-71
   PubMed Web of Science ®Google Scholar
• Samama MM, Mendell J, Guinet C, et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012;129:e77-82
   PubMed Web of Science ®Google Scholar
• Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011;106:429-38
   PubMed Web of Science ®Google Scholar
• Dzik WS. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion 2012;52(Suppl 1):45S-55S
   PubMed Web of Science ®Google Scholar
• Fukuda T, Honda Y, Kamisato C, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012;107:253-9
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Effects of a single-blind, single dose of PER977 administered alone, and following a single dose of edoxaban (PER977-P1). ClinicalTrials gov. 2013. Available from: http://clinicaltrials.gov/show/NCT01826266
   Google Scholar
• Lu G, DeGuzman FR, Lakhotia S, et al. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meeting Abstracts 2008;112:A983
   Google Scholar
• Rohatagi S, Mendell J, Kastrissios H, et al. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. Thromb Haemost 2012;108:887-95
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Hirayama C, Hotoda H, et al. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag 2013;9:593-8
   PubMedGoogle Scholar
• Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41
   PubMed Web of Science ®Google Scholar
• Samama MM, Kunitada S, Oursin A, et al. Study of coagulation and platelets response in an open label randomised non treatment and active controlled (Dalteparin, Ximelagatran and DU- 176b) in 4 groups of elderly healthy subjects. Blood 2008;112:3026
   PubMedGoogle Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708
   PubMed Web of Science ®Google Scholar